Coverage With Evidence Development and Expedited Approvals: Policy Proposals For FDA and CMS
By
Cathy Kelly, Michael McCaughan / Email the Authors / The RPM Report February 2012, Vol. 8, No. 3
CMS Beat / Word Count: 2580 / Article # 2012500038
Executive Summary
Based on stakeholder consultations, former FDA and CMS head Mark McClellan and former CMS official Sean Tunis present a potential upside for biopharma in broader use of Medicare coverage with evidence development. Pfizer executives participate in workshop on coordinating expedited drug approval, CED policies.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.